MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN Patent applications |
Patent application number | Title | Published |
20140077800 | MAGNETIC FIELD APPARATUS AND METHOD OF OPERATING A MAGNETIC FIELD APPARATUS - A magnetic field apparatus comprises a generator for generating a magnetic field of the magnetic field apparatus and a sensor for measuring the interaction between electrical charge carriers in an object and the magnetic field, wherein the electrical as charge carriers and the magnetic field are in relative motion to each other. The magnetic field apparatus may in particular be an MRI apparatus and the sensor may use the magnetohydrodynamic effect for deriving a cardiac trigger signal at any target area positioned off-centre to the heart. | 03-20-2014 |
20140031309 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases - The invention relates to ss-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said ss-f31 L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV). The invention also relates to a method for the preparation of said ss-L-nucleoside and analogs. | 01-30-2014 |
20130165338 | BIOMARKERS FOR DETERMINATION OF TEMPORAL PHASE OF ACUTE KIDNEY INJURY - The invention relates to a method for determining the temporal phase of acute kidney injury, comprising obtaining a test sample from a subject and measuring the expression level of at least one biomarker selected from the group comprising Chac1, Birc5 and Angpt17. The invention also relates to a method for determining the early early phase, the late early phase, the severity and/or timing of acute kidney injury via analysis of the biomarkers Chac1, Birc5 and/or Angptl7, in addition to a test kit for carrying out said methods and antibodies directed against Chac1, Birc5 or Angptl7. | 06-27-2013 |
20130136717 | THERAPEUTIC USE OF AGONISTS OR ANTAGONISTS OF BRADYKININ RECEPTOR 1 OR 2, FOR MODULATION COLLATERAL BLOOD VESSEL GROWTH - The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and/or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and/or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease. | 05-30-2013 |
20130078186 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES - The present invention relates to compounds suitable as modulators of protein misfolding and/or protein aggregation. The compounds are particularly suitable as inhibitors of amyloid aggregate formation and/or modulators of amyloid surface properties, and/or as activators of degradation or reduction of amyloid aggregates. | 03-28-2013 |
20120128704 | REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF - The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin. | 05-24-2012 |
20100255041 | REMEDY FOR THE TREATMENT OF CARDIO-VASCULAR DISEASES OR DISORDERS - Disclosed is the use of inhibitors of β-catenin expression or activity or modulators downregulating β-catenin expression or activity for the treatment of cardiovascular diseases or disorders and their use in the treatment of cardiovascular diseases and disorders, such as heart failure syndrome. The use of those agents resulted in particular in cardiomyocyte differentiation of endogenous cardiac stem cells. | 10-07-2010 |
20090220469 | PEPTIDES AGAINST AUTOANTIBODIES ASSOCIATED WITH GLAUCOMA AND USE OF THESE PEPTIDES - The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma. | 09-03-2009 |
20090105186 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases - The invention relates to β-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said β-L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV). The invention also relates to a method for the preparation of said β-L-nucleoside analogs. | 04-23-2009 |
20090023662 | Identification of Agonistic Autoantibodies Associated with Humoral Kidney Rejection - The invention relates to a method for detecting autoantibodies associated with humoral kidney rejection, which recognize extracellular structures of G protein-coupled receptors, and to the use of peptides, which comprise these loops or fragments thereof, for treating humoral kidney rejection. | 01-22-2009 |
20080292550 | Fluorinated 3'-Deoxythymidine Derivatives, a Method for Their Preparation and Their Use - The invention relates to new side chain-fluorinated 3′-deoxythymidine derivatives of the general formula I | 11-27-2008 |